



**Doptelet® (avatrombopag)
Mulpleta® (lusutrombopag)
Effective 01/01/2022**

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Doptelet and Mulpleta are thrombopoietin receptor agonists indicated for the treatment of thrombocytopenia in adults.

Coverage Guidelines

Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with the requested excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR

Authorization may be granted if all the following criteria is met and documentation has been submitted:

Doptelet

1. The member is at least 18 years of age
2. The member has diagnosis of chronic ITP
3. The member has platelet counts of <30,000 cells/microliter
4. The member has had an inadequate response, adverse reaction or contraindication to one corticosteroid and immunoglobulin OR the member has had a splenectomy.

OR

1. The member has a diagnosis of chronic liver disease and thrombocytopenia
2. The member is at least 18 years of age
3. The member has a platelet count of < 50,000 cells/microliter AND
4. The member is scheduled to undergo a procedure (date of planned procedure is documented)
Therapy should be initiated 10-13 days prior to scheduled procedure



Mulpleta

Authorization may be granted if all the following criteria is met and documentation has been submitted:

1. The member is at least 18 years of age
2. The member has a diagnosis of chronic liver disease *and* thrombocytopenia
3. The member has a platelet count of <50,000 cells/microliter
4. The member is scheduled to undergo a procedure (date of planned procedure is documented)
Therapy should be initiated 8-14 days prior to scheduled procedure

Continuation of Therapy

Reauthorizations for members with a diagnosis of Chronic ITP require documentation of improvement in platelet counts.

Limitations

1. Approvals for members with a diagnosis of chronic liver disease and thrombocytopenia who will be undergoing a procedure, will be issued for 1 month for one course of therapy per authorization
2. Initial and reauthorizations for members with a diagnosis of Chronic ITP will be issued for 6 months
3. The following quantity limits apply:

Doptelet	10 tablets for members with platelet count of 40,000 to <50,000 cells/microliter per procedure 15 tablets for members with platelet count of <40,000 cells/microliter per procedure
Mulpleta	7 tablets per procedure
Doptelet (ITP)	#60 tablets per 30 days

References

1. Doptelet (avatrombopag) [prescribing information]. Durham, NC: Dova Pharmaceuticals, Inc; Revised: June 2019
2. Mulpleta (lusutrombopag) [prescribing information]. Florham Park, NJ: Shionogi Inc; April 2020
3. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. *Blood* 2014; 123:3887.
4. Bylsma LC, Fryzek JP, Cetin K, et al. Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. *Am J Hematol* 2019; 94:118.
5. Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients with Chronic Liver Disease and Thrombocytopenia. *Gastroenterology* 2018; 155:705.
6. Katsube T, Ishibashi T, Kano T, Wajima T. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. *Clin Pharmacokinet* 2016; 55:1423.
7. Kim ES. Lusutrombopag: First Global Approval. *Drugs* 2016; 76:155.
8. Maan R, de Knecht RJ, Veldt BJ. Management of thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies. *Drugs*. 2015; 75:1981-92.

Review History

02/20/2019 – Approved by P&T



09/18/2019 - Added new indication of treatment of chronic ITP

09/16/2020 – Updated and Reviewed Sept P&T Mtg; Updated Platelet count for chronic ITP <30,000; references updated. Effective 12/1/20

09/22/2021 – Reviewed Sept P&T; started and stabilized statement updated to include members to new AllWays Health Partners. Effective 01/01/2022

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.